Clinical Trial Conduct Investigations Are “Coming Storm” For Rx Industry, U.S. Attorney Sheehan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Investigations into institutional review board practices will likely focus on compliance with subject disclosure and protection issues, Sheehan tells the International Pharmaceutical Compliance Summit in Philadelphia.